Oppenheimer Reiterates Outperform on Vertex Pharmaceuticals, Maintains $410 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Hartaj Singh has reiterated an 'Outperform' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $410.
August 04, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Hartaj Singh has reiterated an 'Outperform' rating on Vertex Pharmaceuticals and maintained a price target of $410.
The reiteration of an 'Outperform' rating and a high price target by a reputable analyst like Hartaj Singh from Oppenheimer is a positive signal for Vertex Pharmaceuticals. This could potentially lead to an increase in investor confidence and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100